1
|
Magana M, Vergez S, Verillaud B, Garrel R, Evrard D, Mouawad F, de Gabory L, Fakhry N, Jegoux F, Malard O, Bach C, Philouze P, Aubry K, Mauvais O, Moya Plana A, Marie JP, Baujat B, Atallah S. Natural history of salivary gland secretory carcinoma: A REFCOR study. Surg Oncol 2024; 57:102159. [PMID: 39486243 DOI: 10.1016/j.suronc.2024.102159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2024] [Revised: 10/21/2024] [Accepted: 10/24/2024] [Indexed: 11/04/2024]
Abstract
BACKGROUND AND OBJECTIVES Salivary gland Secretory Carcinoma (SC), characterized by Skalova in 2010 is a rare tumor studied within the REFCOR (French Network of experts on Rare Head and Neck Cancers). We conducted a prospective multicentric cohort study of 108 SC cases in the REFCOR database up to July 2021, analyzing diagnostic, therapeutic, and survival data. METHODS Data was collected prospectively from diagnosis to the last update. Each patient had two histological readings including one by a REFCORpath pathologist, and all cases underwent molecular testing to confirm diagnosis. Statistical analyses were performed using R software. RESULTS MRI was not contributive to malignancy diagnosis. After 2 histological readings, 79 % of patients were diagnosed, with 21 % requiring molecular testing to confirm diagnosis. Surgical treatment typically involved tumor excision and lymph node dissection. The tumor exhibited low lymph node involvement, with 95 % of patients being cN0, and no nodal metastases post-dissection. Five-year overall survival and recurrence-free survival were 91.4 % {95 % CI (0.84-1)} and 89 % {95 % CI (0.81; 0.98)} respectively, indicating a favorable prognosis. CONCLUSIONS SC is a rare and newly recognized tumor, with generally favorable outcomes. Our cohort, among the largest to date, provides valuable insights. Future research should refine treatment guidelines.
Collapse
Affiliation(s)
- Marie Magana
- Sorbonne University, Tenon Hospital, APHP, ENT and Head and Neck Surgery Department, 4 Rue de la Chine, 75020, Paris, France.
| | - Sebastien Vergez
- Toulouse University, IUCT, ENT and Head and Neck Department, 1 Avenue Irene Joliot-Curie, 31100, Toulouse, France.
| | - Benjamin Verillaud
- Paris-Cite University, Lariboisiere Hospital, APHP, ENT Department, 2 Rue Ambroise Pare, 75010, Paris, France.
| | - Renaud Garrel
- Montpellier-Nimes University, Gui de Chaulliac Hospital, CHU Montpellier, ENT and Head and Neck Surgery Department, 80 Avenue Augustin Fliche, 34295, Montpellier, France.
| | - Diane Evrard
- Paris-Cite University, Bichat Hospital, 46 Rue Henri Huchard, APHP, ENT and Head and Neck Surgery Department, 75018, Paris, France.
| | - François Mouawad
- Lille University, Claude Huriez Hospital, CHU Lille, Head and Neck Surgery Department, UMR9020 CNRS - U1277 Inserm, 59037, 1 Place de Verdun, Lille, France.
| | - Ludovic de Gabory
- Bordeaux University, Pellegrin Hospital, CHU Bordeaux, Head and Neck Surgery Department, Place Amélie Raba-Léon, 33076, Bordeaux, France.
| | - Nicolas Fakhry
- Aix-Marseille University, Conception Hospital, APHM, ENT and Head and Neck Surgery Department, 147 Boulevard Baille, 13005, Marseille, France.
| | - Franck Jegoux
- Rennes University, Pontchaillou Hospital, CHU Rennes, ENT Department, 2 Rue Henri Le Guilloux, 35000, Rennes, France.
| | - Olivier Malard
- Nantes University, Hotel-Dieu Hospital, CHU Nantes, ENT and Head and Neck Surgery Department, 1 Place Alexis-Ricordeau, 44000, Nantes, France.
| | - Christine Bach
- Ambroise Pare-Hartmann Private Hospital, 48 ter boulevard Victor Hugo, 92200, Neuilly-sur-Seine, France.
| | - Pierre Philouze
- Claude Bernard Lyon 1 University, Croix Rousse Hospital, HCL, Head and Neck Surgery Department, 103 Grand Rue de la Croix-Rousse, 69004, Lyon, France.
| | - Karine Aubry
- Limoges University, Dupuytren Hospital, CHU Limoges, ENT and Head and Neck Surgery Department, 2 Avenue Martin Luther King, 87000, Limoges, France.
| | - Olivier Mauvais
- Besancon University, Jean Minjoz Hospital, ENT and Head and Neck Surgery Department, 3 boulevard Alexandre Fleming, 25000, Besançon, France.
| | - Antoine Moya Plana
- Paris Saclay University, Gustave Roussy Institute, Head and Neck Surgery Department, INSERM U981, 114 Rue Edouard Vaillant, 94805, Villejuif, France.
| | - Jean Paul Marie
- Rouen University, Charles-Nicolle Hospital, CHU Rouen, ENT and Head and Neck Surgery Department, 37 boulevard Gambetta, 76000, Rouen, France.
| | - Bertrand Baujat
- Sorbonne University, Tenon Hospital, APHP, ENT and Head and Neck Surgery Department, 4 Rue de la Chine, 75020, Paris, France.
| | - Sarah Atallah
- Sorbonne University, Tenon Hospital, APHP, ENT and Head and Neck Surgery Department, 4 Rue de la Chine, 75020, Paris, France.
| |
Collapse
|
2
|
Serrano-Meneses GJ, Brenes Guzmán S, Serrano-Meneses MA, Delgado-Porras A. Insights Into Pediatric Secretory Carcinoma of the Salivary Gland: A Case Report. Cureus 2024; 16:e60355. [PMID: 38883019 PMCID: PMC11178125 DOI: 10.7759/cureus.60355] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/15/2024] [Indexed: 06/18/2024] Open
Abstract
Secretory carcinoma of the salivary gland (SCSG) is a rare head and neck tumor in adults and exceptional at the pediatric age. Its varied histological subtypes and distinct clinical presentation pose diagnostic and therapeutic challenges. Therefore, standardized guidelines are of utmost importance for the care of these patients, especially in children. Here we present an 11-year-old male presented with a left cheek mass initially diagnosed as lipoma. A wide resection was performed and SCSG was revealed in the histopathologic and immunohistochemistry analysis. The presentation of this case provides valuable information on the diagnostic and therapeutic complexities of SCSG. It emphasizes the need for standardized guidelines and further research to optimize pediatric patient outcomes. Overall, this case report is a crucial resource for clinicians and researchers, highlighting the importance of interdisciplinary collaboration and early intervention in managing SCSG.
Collapse
Affiliation(s)
| | - Sofia Brenes Guzmán
- Pediatric Surgical Oncology, Hospital Infantil Privado, Star Médica, Mexico City, MEX
| | | | - Alberto Delgado-Porras
- Pediatric and Neonatal Surgery, Hospital Infantil Privado, Star Médica, Mexico City, MEX
| |
Collapse
|
3
|
Yosefof E, Boldes T, Dan D, Robenshtok E, Strenov Y, Bachar G, Shpitzer T, Mizrachi A. Salivary Gland Secretory Carcinoma; Review of 13 Years World-Wide Experience and Meta-Analysis. Laryngoscope 2024; 134:1716-1724. [PMID: 37909690 DOI: 10.1002/lary.31123] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2023] [Revised: 09/15/2023] [Accepted: 10/10/2023] [Indexed: 11/03/2023]
Abstract
OBJECTIVES Secretory Carcinoma is a malignant salivary gland tumor, initially described in 2010. This rare tumor is associated with the translocation t(12;15) (p13;q25), resulting in the fusion gene ETV6-NTRK3. Since this tumor is quite rare, most publications describe only small cohorts of patients. We aimed to investigate the clinical, pathological, and prognostic features of this newly defined malignant entity. DATA SOURCES Pubmed, Google Scholar, and Web of Science databases. REVIEW METHODS All published articles between 2010 and 2023 were reviewed. Search terms included the terms "Mammary Analogue Secretory Carcinoma" and "Secretory Carcinoma". All articles published in English reporting on Secretory Carcinoma of salivary glands were retrieved. RESULTS One-hundred and 12 retrospective articles reporting a total of 674 patients were included, with 52% males and a mean age of 44.9 ± 18.9. The event rate for patients with advanced-stage disease (Stage 3/4) at presentation was 24.1% (95% CI 17.6%-31.9%, I2 = 9.2%), 14.6% for regional metastases (95% CI 10.5%-20%, I2 = 12%), and the event rate of distant metastasis was 8.4% (95% CI 5.5%-12.7%, I2 = 4.2%). Adjuvant radiotherapy was administered for 30.3% of patients (95% CI 24.1%-37.2%, I2 = 21.5%). The recurrence rate was 19% (95% CI 15.1%-23.8%, I2 = 5%). Survival outcomes showed a 17.2% death of disease rate for Secretory Carcinoma patients (95% CI 13.5%-21.8%, I2 = 7.3%). CONCLUSIONS Secretory Carcinoma is a rare and relatively newly defined entity arising in the parotid gland most commonly. Characterized as a low-grade tumor, the majority of patients are diagnosed at an early stage, without regional or distant disease, and the prognosis is relatively good. LEVEL OF EVIDENCE NA Laryngoscope, 134:1716-1724, 2024.
Collapse
Affiliation(s)
- Eyal Yosefof
- Department of Otorhinolaryngology and Head and Neck Surgery, Rabin Medical Center-Beilinson Hospital, Petach Tikva, Israel
- Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Tomer Boldes
- Department of Otorhinolaryngology and Head and Neck Surgery, Rabin Medical Center-Beilinson Hospital, Petach Tikva, Israel
- Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Daniel Dan
- Department of Otorhinolaryngology and Head and Neck Surgery, Rabin Medical Center-Beilinson Hospital, Petach Tikva, Israel
- Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Eyal Robenshtok
- Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
- Institute of Endocrinology, Diabetes and Metabolism, Rabin Medical Center, Petah Tikva, Israel
| | - Yulia Strenov
- Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
- Department of Pathology, Rabin Medical Center, Petah Tikva, Israel
| | - Gideon Bachar
- Department of Otorhinolaryngology and Head and Neck Surgery, Rabin Medical Center-Beilinson Hospital, Petach Tikva, Israel
- Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Thomas Shpitzer
- Department of Otorhinolaryngology and Head and Neck Surgery, Rabin Medical Center-Beilinson Hospital, Petach Tikva, Israel
- Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Aviram Mizrachi
- Department of Otorhinolaryngology and Head and Neck Surgery, Rabin Medical Center-Beilinson Hospital, Petach Tikva, Israel
- Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| |
Collapse
|